ADARx Pharmaceuticals, Inc. (ADRX)
ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXIndustrials · Specialty Business Services
-0.28%$17.63
AH Close$17.63+0.00%vs close
AH Close$17.63+0.00%vs close
Mkt Cap$1.88B
Float52.5M
O/S106.8M
Inst Own-
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
Key Metrics
Market Cap$1.88B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.00%
based on 106.80M shares outstanding
SectorIndustrials
IndustrySpecialty Business Services
ExchangeNASDAQ
Country--
IPO DateSep 25, 2026
Shares Outstanding106.80M
Float52.50M
Company Overview
No company description available.
Leadership
Zhen Li
Co-Founder, President, CEO & Director
Robert A. MacLeod
Chief Scientific Officer
Employees
--
Country
--
Sector
Industrials
Website
--
Analyst Coverage
Analyst Coverage
Price Target (median, last 90d)
$33.50+90.0%
Low $32High $35
Ratings
N/AInsider Trading
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 LAV Biosciences Fund V, L.P. | 10% Owner | Conversion of Derivative | 360.6K | -- | Sep 28, 2026 |
 SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Conversion of Derivative | 1.11M | -- | Sep 28, 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Conversion of Derivative | 512.9K | -- | Sep 28, 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Purchase | 592.6K | $10.07M | Sep 28, 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Conversion of Derivative | 1.54M | -- | Sep 28, 2026 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner | Purchase | 414.8K | $7.05M | Sep 28, 2026 |
Shareholders
0.0%
Institutional
(0)
2.4%
Insiderⓘ
(1)
40.7%
5%+ Owners
(4)
57.0%
Unattributed (incl. retail)ⓘ
Insider2.4%
5%+ Beneficial40.7%
Unattributed (incl. retail)57.0%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
ORBIMED ADVISORS LLC · joint filing· may incl. warrants· filed Oct 2026 | 14.9M | 14.0% | 13D |
Yi Shi · joint filing· may incl. warrants· filed Oct 2026 | 11.9M | 11.1% | 13G |
SR One Capital Management, LLC · joint filing· may incl. warrants· filed Oct 2026 | 9.9M | 9.3% | 13D |
BCLS Fund III Investments, LP · may incl. warrants· filed Oct 2026 | 6.7M | 6.3% | 13G |
 Zhu Rui (NMN) Chief Technology Officer | 2.5M | 2.4% | FORM 4 |
Sources: Form 4, 13D/13GO/S: 106.8M · checked 25 Oct 2026 · market-data provider
Insiders & Institutional Holders
Insiders
- LAV Biosciences Fund V, L.P.10% Owner
- SR ONE CAPITAL MANAGEMENT, LLC10% Owner
- George SimeonDirector
- MacLeod Alan RobertChief Scientific Officer
- Fisk RyanCFO and CBO
- Li ZhenPresident and CEO
- Ackles Robert WilliamChief People Officer
- Zhu Rui (NMN)Chief Technology Officer
Key Metrics
Market Cap$1.88B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership0.00%
based on 106.80M shares outstanding
SectorIndustrials
IndustrySpecialty Business Services
ExchangeNASDAQ
Country--
IPO DateSep 25, 2026
Shares Outstanding106.80M
Float52.50M
52-Week Range
Volume
Average Daily Volume624.07K
176.94K today vs 624.07K avg(-72%)
30d Avg
624.07K
60d Avg
795.01K
90d Avg
795.01K
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...